A recent study reveals that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional lifestyle plans.
Published data in a leading health publication points out that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these medications must be aware of the danger of quick weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting weight within about a year and a half.
Comparing Treatments
The research, which reviewed dozens of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
The team point out that individuals who lose weight through diet and exercise generally have a less rapid creep back—perhaps 100 grams monthly—after stopping.
Understanding the Rapid Regain
Doctors propose the mode of action of the drugs is key to understanding the accelerated weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to appetite is unsuppressed, making binge eating far more likely."
A Chronic Disease?
The NHS suggest the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of weight regain, the treatment might need to be long-term.
This view is supported by pharmaceutical companies, who say that the findings "highlight the persistent nature of obesity," similar to managing diseases like hypertension.
Patient Testimonies
People who have discontinued the medication describe a powerful return of appetite.
"It was like something activating and I was suddenly starving," described an individual.
This difficulty is worsened if users have not developed lasting lifestyle or habit changes during therapy.
Widespread Interest
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is more common among females than males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and maintained weight loss likely depends on integrated lifestyle support.
